TapewireFind a company

person · Reporting owner

Grossman Adam S

Disclosed activity across 1 company

Tapewire entity
59867
SEC CIK
0001542517

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADMA BIOLOGICS, INC.ADMA · Entity 4477Director · President and CEOMarch 16, 2026March 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date March 16, 2026 · Filed March 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,133,777 Reported balance After 2026-03-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-03-16 · Exercise / conversion · Acquired 15,000 · Balance 2,133,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

Common StockSEC Table I · non-derivativeDirect2,118,777 Reported balance After 2026-03-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-03-16 · Sale · Disposed 15,000 · Balance 2,118,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

Common StockSEC Table I · non-derivativeDirect2,112,777 Reported balance After 2026-03-16 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2026-03-16 · Sale · Disposed 6,000 · Balance 2,112,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2034-02-26Direct690,950 Reported balance After 2026-03-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-03-16 · Exercise / conversion · Disposed 15,000 · Balance 690,950

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,143,426 Reported balance Holding disclosure · report date 2026-03-16 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 1,143,426

F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

Common StockSEC Table I · non-derivativeIndirectSee Footnote580,957 Reported balance Holding disclosure · report date 2026-03-16 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 580,957

F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 1,589,987 $4.61 $7,329,840.07
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 8

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,523,088

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 510,469 $4.54 $2,318,958.57
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 7

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,113,075

F1 · price: Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.495 to $4.63, inclusive.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 583,224 $3.66 $2,134,599.84
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,623,544

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 350,000 $3.71 $1,298,500.00
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 5

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,040,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 400,000 $3.22 $1,288,000.00
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,690,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 277,604 $2.92 $809,215.66
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,290,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 277,131 $2.35 $651,257.85
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,012,716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 18, 2023 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 212,500 $1.67 $354,875.00
Disclosure

SEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,735,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 30, 2023 Filed Jul 6, 2023 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 20,051 $3.69 $73,988.19
Disclosure

SEC source: 0001140361-23-033190 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,523,085

F1 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,254,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 31, 2023 Filed Apr 5, 2023 01:06 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 17,853 $3.31 $59,093.43
Disclosure

SEC source: 0001140361-23-016458 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,543,139

F1 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 397,032 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,218,071 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 23,607 $3.40 $80,263.80
Disclosure

SEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 5

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,560,992

F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,179,206 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

F4 · balance_after: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 1,147,385 $0.00 Strike: $3.35 $0.00
Disclosure

SEC source: 0001140361-23-010774 · form4.xml · derivative · entry 8

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,147,385

Underlying: Common Stock · 1,147,385 shares

Expires 2033-03-06

F6 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 573,695 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,584,599

F1 · shares: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 453,750 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

Read SEC document
February 28, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 7,507 $3.55 $26,649.85
Disclosure

SEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,010,904

Read SEC document
February 25, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 14,412 $3.42 $49,289.04
Disclosure

SEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,018,411

Read SEC document
February 25, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 4,018 $3.42 $13,741.56
Disclosure

SEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,032,823

Read SEC document
January 04, 2023 Filed Jan 7, 2023 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 166,867 $3.87 $645,775.29
Disclosure

SEC source: 0001140361-23-000873 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,036,841

F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 453,750 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 1,070,198 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
December 09, 2022 Filed Dec 9, 2022 21:41 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 14,982 $2.86 $42,848.52
Disclosure

SEC source: 0001140361-22-045111 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,143,426

F1 · shares: Represents a purchase from the underwriters in the December 2022 public offering of the issuer.

F5 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

Read SEC document
December 09, 2022 Filed Dec 9, 2022 21:41 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 14,983 $2.86 $42,851.38
Disclosure

SEC source: 0001140361-22-045111 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,203,708

F1 · shares: Represents a purchase from the underwriters in the December 2022 public offering of the issuer.

F2 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (continued)

F3 · balance_after: (continued from prior footnote) (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (continued)

F4 · balance_after: (continued from prior footnote) (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 783,315 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 30, 2022 Filed Oct 5, 2022 01:21 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 101,315 $2.43 $246,195.45
Disclosure

SEC source: 0001140361-22-036164 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,188,725

F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's (continued)

F2 · balance_after: (continued from prior footnote) continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 768,332 shares of common stock owned by the reporting person, which reflects previous purchases and prior net settlements upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
May 11, 2022 Filed May 14, 2022 01:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 70,004 $1.43 $100,105.72
Disclosure

SEC source: 0001140361-22-019215 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,290,040

F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 330,412 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the

F2 · balance_after: (continued from footnote 1) Compensation Committee of the Board of Directors, which shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's

F3 · balance_after: (continued from footnote 2) continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 539,234 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 23, 2022 Filed Mar 25, 2022 21:15 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 50,539 $1.46 $73,786.94
Disclosure

SEC source: 0001140361-22-011249 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,360,044

F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 577,665 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the

F2 · balance_after: (continued from footnote 1) Compensation Committee of the Board of Directors, of which (x) 247,253 of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (y) 330,412 of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting

F3 · balance_after: (continued from footnote 2) 2. person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 361,986 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 22:58 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 600,000 $0.00 Strike: $1.67 $0.00
Disclosure

SEC source: 0001140361-22-008671 · form4.xml · derivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2032-03-07

F8 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 22:58 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 300,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-008671 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,410,583

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 907,500 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F3 · balance_after: (continue from footnote 2) (iii) 742,500 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting,

F4 · balance_after: (continue from footnote 3) subject to the reporting person's continued employment on the applicable vesting date; (iv) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F5 · balance_after: (continue from footnote 4) (v) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 247,690 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
October 25, 2021 Filed Oct 26, 2021 11:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 250,000 $1.00 $250,000.00
Disclosure

SEC source: 0001140361-21-035379 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,128,444

F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer.

F6 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

Read SEC document
October 25, 2021 Filed Oct 26, 2021 11:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 100,000 $1.00 $100,000.00
Disclosure

SEC source: 0001140361-21-035379 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,137,616

F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer.

F2 · balance_after: Includes (i) 907,500 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F3 · balance_after: (ii) 742,500 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F4 · balance_after: (iii) 221,447 RSUs granted on February 25, 2021, of which 183,150 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 38,297 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F5 · balance_after: (iv) 75,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 191,169 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 29, 2021 Filed Oct 2, 2021 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 742,500 $0.00 $0.00
Disclosure

SEC source: 0001140361-21-033354 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,037,616

F2 · shares: These shares represent RSUs that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022.

F3 · balance_after: Includes (i) 907,500 Time-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and that will be settled into common stock upon vesting; (ii) 742,500 Milestone-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (2) and that will be settled into common stock upon vesting; (iii) 221,447 RSUs granted on February 25, 2021, of which 183,150 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 38,297 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iv) 75,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 91,169 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 29, 2021 Filed Oct 2, 2021 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 907,500 $0.00 $0.00
Disclosure

SEC source: 0001140361-21-033354 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,295,116

F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024.

Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 458,700 $0.00 Strike: $2.35 $0.00
Disclosure

SEC source: 0001193805-21-000293 · e620328_4-agrossman.xml · derivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,700

Underlying: Common Stock · 458,700 shares

Expires 2031-02-25

F5 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.

Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 221,447 $0.00 $0.00
Disclosure

SEC source: 0001193805-21-000293 · e620328_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 397,545

F1 · shares: These shares represent restricted stock units ("RSUs"). Of these RSUs, 183,150 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 38,297 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 221,447 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 100,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (iii) 76,098 shares of common stock owned by the reporting person.

Read SEC document
September 08, 2020 Filed Sep 10, 2020 12:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 4,000 $2.24 $8,959.60
Disclosure

SEC source: 0001193805-20-001128 · e619921_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,098

F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting.

Read SEC document
August 11, 2020 Filed Aug 12, 2020 12:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 1,000 $2.97 $2,970.00
Disclosure

SEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,098

F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting.

Read SEC document
August 10, 2020 Filed Aug 12, 2020 12:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 2,000 $3.04 $6,080.00
Disclosure

SEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,098

F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting.

Read SEC document
August 10, 2020 Filed Aug 12, 2020 12:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 2,990 $3.07 $9,179.30
Disclosure

SEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,098

F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting.

Read SEC document
August 10, 2020 Filed Aug 12, 2020 12:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 10 $3.06 $30.60
Disclosure

SEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,108

F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting.

Read SEC document
February 28, 2020 Filed Mar 4, 2020 00:08 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 325,000 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001193805-20-000287 · e619421_4-agrossman.xml · derivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,000

Underlying: Common Stock · 325,000 shares

Expires 2030-02-28

F5 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.

Read SEC document
February 28, 2020 Filed Mar 4, 2020 00:08 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001193805-20-000287 · e619421_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,098

F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 100,000 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 66,098 shares of common stock owned by the reporting person.

Read SEC document
February 11, 2020 Filed Feb 11, 2020 15:11 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 57,143 $3.50 $200,000.50
Disclosure

SEC source: 0001193805-20-000127 · e619338_4-agrossman.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 878,444

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

Read SEC document
February 11, 2020 Filed Feb 11, 2020 15:11 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 28,571 $3.50 $99,998.50
Disclosure

SEC source: 0001193805-20-000127 · e619338_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,098

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
May 17, 2019 Filed May 21, 2019 11:11 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 25,000 $4.00 $100,000.00
Disclosure

SEC source: 0001193805-19-000520 · e618479_4-agrossman.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 821,301

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

Read SEC document
May 17, 2019 Filed May 21, 2019 11:11 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 5,000 $4.00 $20,000.00
Disclosure

SEC source: 0001193805-19-000520 · e618479_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,527

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
January 23, 2019 Filed Jan 26, 2019 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 400,000 $0.00 Strike: $3.22 $0.00
Disclosure

SEC source: 0001193805-19-000090 · e618164_4-agrossman.xml · derivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2029-01-23

F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 11:09 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 52,301 $4.78 $249,998.78
Disclosure

SEC source: 0001193805-18-000820 · e618086_4-agrossman.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 796,301

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 11:09 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 20,921 $4.78 $100,002.38
Disclosure

SEC source: 0001193805-18-000820 · e618086_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,527

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
February 09, 2018 Filed Feb 14, 2018 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 350,000 $0.00 Strike: $3.71 $0.00
Disclosure

SEC source: 0001193805-18-000188 · e617682_4-agrossman.xml · derivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2028-02-09

F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:46 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 485,000 $2.15 $1,042,750.00
Disclosure

SEC source: 0001193805-17-003451 · e617469_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 744,000

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.

Read SEC document
July 13, 2017 Filed Jul 17, 2017 21:14 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 42,021 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · derivative · entry 5

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,021 shares

Expires 2017-07-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on July 16, 2007 (the "First Anniversary Date"), and the remaining seventy-five percent (75%) of the shares subject to the option vested in equal monthly installments over the three (3) year period following the First Anniversary Date.

Read SEC document
July 13, 2017 Filed Jul 17, 2017 21:14 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 34,126 $3.30 $112,615.80
Disclosure

SEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,606

Read SEC document
July 13, 2017 Filed Jul 17, 2017 21:14 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 42,021 $2.68 $112,616.28
Disclosure

SEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 06, 2017 Filed Jun 8, 2017 22:03 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 583,224 $0.00 Strike: $3.66 $0.00
Disclosure

SEC source: 0001193805-17-001059 · e616266_4-agrossman.xml · derivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 583,224

Underlying: Common Stock · 583,224 shares

Expires 2027-06-06

F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.